A phase II trial of Rituxan [rituximab] and BEAM [carmustine, etoposide, cytarabine, and melphalan] high-dose chemotherapy and autologous peripheral blood progenitor transplant for lymphoma

Trial Profile

A phase II trial of Rituxan [rituximab] and BEAM [carmustine, etoposide, cytarabine, and melphalan] high-dose chemotherapy and autologous peripheral blood progenitor transplant for lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Rituximab (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2012 Company (Genentech) added as reported by ClinicalTrials.gov.
    • 23 Mar 2012 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
    • 23 Mar 2012 Status changed from active, no longer recruiting to completed added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top